The deal will give Gilead access to CymaBay’s lead drug candidate called seladelpar, adding a treatment for chronic liver disease to its portfolio.

Was this article helpful?

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Close Search Window